AU2017378060B2 - 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors - Google Patents
7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors Download PDFInfo
- Publication number
- AU2017378060B2 AU2017378060B2 AU2017378060A AU2017378060A AU2017378060B2 AU 2017378060 B2 AU2017378060 B2 AU 2017378060B2 AU 2017378060 A AU2017378060 A AU 2017378060A AU 2017378060 A AU2017378060 A AU 2017378060A AU 2017378060 B2 AU2017378060 B2 AU 2017378060B2
- Authority
- AU
- Australia
- Prior art keywords
- ethyl
- compound
- phenyl
- oxazin
- mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020260493A AU2020260493B2 (en) | 2016-12-16 | 2020-10-29 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662435283P | 2016-12-16 | 2016-12-16 | |
| US62/435,283 | 2016-12-16 | ||
| PCT/US2017/065246 WO2018111707A1 (en) | 2016-12-16 | 2017-12-08 | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020260493A Division AU2020260493B2 (en) | 2016-12-16 | 2020-10-29 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017378060A1 AU2017378060A1 (en) | 2019-05-30 |
| AU2017378060B2 true AU2017378060B2 (en) | 2020-09-03 |
Family
ID=60888651
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017378060A Active AU2017378060B2 (en) | 2016-12-16 | 2017-12-08 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors |
| AU2020260493A Active AU2020260493B2 (en) | 2016-12-16 | 2020-10-29 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020260493A Active AU2020260493B2 (en) | 2016-12-16 | 2020-10-29 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors |
Country Status (37)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE062424T2 (hu) | 2014-09-19 | 2023-11-28 | Forma Therapeutics Inc | Piridin-2(1H)-on kinolinon származékok mint mutáns izocitrát dehidrogenáz inhibitorok |
| CA2961807A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| WO2016044781A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors |
| WO2016044787A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| US9624175B2 (en) | 2015-04-21 | 2017-04-18 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| US10407419B2 (en) | 2015-04-21 | 2019-09-10 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
| UA125824C2 (uk) | 2016-10-24 | 2022-06-15 | Астразенека Аб | 6,7,8,9-ТЕТРАГІДРО-3H-ПІРАЗОЛО[4,3-f]ІЗОХІНОЛІНОВІ ПОХІДНІ, ЗАСТОСОВНІ В ЛІКУВАННІ РАКУ |
| JP6793836B2 (ja) * | 2016-12-16 | 2020-12-02 | イーライ リリー アンド カンパニー | 変異体ｉｄｈ１およびｉｄｈ２阻害剤としての７−フェニルエチルアミノ−４ｈ−ピリミド［４，５−ｄ］［１，３］オキサジン−２−オン化合物 |
| MX2022004474A (es) | 2016-12-16 | 2023-08-15 | Janssen Pharmaceutica Nv | Inhibidores de moléculas pequeñas de la familia de quinasas jak. |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| CR20190379A (es) | 2017-01-30 | 2019-10-21 | Astrazeneca Ab | Moduladores del receptor de estrógeno |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
| US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| WO2019222551A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| SMT202300073T1 (it) | 2018-05-16 | 2023-05-12 | Forma Therapeutics Inc | Inibizione di idh-1 mutante |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| WO2021089395A1 (en) * | 2019-11-08 | 2021-05-14 | Nerviano Medical Sciences S.R.L. | Gem-disubstituted heterocyclic compounds and their use as idh inhibitors |
| MX2022011846A (es) * | 2020-03-23 | 2023-01-04 | Lilly Co Eli | Metodo para el tratamiento de sujetos resistentes al inhibidor idh1. |
| AU2021242260B2 (en) * | 2020-03-23 | 2023-12-14 | Eli Lilly And Company | Combination therapy with a mutant IDH inhibitor |
| EP4125917B1 (en) * | 2020-03-23 | 2024-04-17 | Eli Lilly and Company | Combination therapy with a mutant idh inhibitor and a bcl-2 inhibitor |
| US20210330653A1 (en) | 2020-04-24 | 2021-10-28 | Astrazeneca Ab | Dosage Regimen for the Treatment of Cancer |
| PE20221838A1 (es) | 2020-04-24 | 2022-11-29 | Astrazeneca Ab | Formulaciones farmaceuticas |
| CN115768775B (zh) * | 2020-06-28 | 2024-10-25 | 微境生物医药科技(上海)有限公司 | Idh突变体抑制剂及其用途 |
| CA3186786A1 (en) * | 2020-07-20 | 2022-01-27 | David Michael HYMAN | Combination therapy with a mutant idh1 inhibitor, a deoxyadenosine analog, and a platinum agent |
| US12390451B2 (en) | 2021-03-11 | 2025-08-19 | Janssen Pharmaceutica Nv | Small molecule inhibitor of the JAK family of kinases |
| CN113588768B (zh) * | 2021-05-18 | 2022-07-05 | 国家卫生健康委科学技术研究所 | 一种以分子图像方式定量组织内内源性代谢物的质谱方法 |
| US20240261294A1 (en) * | 2021-06-09 | 2024-08-08 | Eli Lilly And Company | Method for treating idh inhibitor-resistant subjects |
| BR112023024454A2 (pt) * | 2021-06-15 | 2024-02-06 | Wigen Biomedicine Tech Shanghai Co Ltd | Composto de fórmula geral (1) ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; e; uso do composto ou do isômero |
| EP4384273A1 (en) | 2021-08-13 | 2024-06-19 | Eli Lilly and Company | Solid forms of 7-[[(1s)-1-[4-[(1s)-2-cyclopropyl-1-(4-prop-2- enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4h- pyrimido[4,5-d] [1,3]oxazin-2-one |
| WO2023141087A1 (en) | 2022-01-19 | 2023-07-27 | Eli Lilly And Company | Combination therapy with a mutant idh inhibitor |
| US20250049809A1 (en) * | 2023-07-31 | 2025-02-13 | Board Of Regents, The University Of Texas System | Inhibitors of mutant idh1 and idh2 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013046136A1 (en) * | 2011-09-27 | 2013-04-04 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| WO2016171755A1 (en) * | 2015-04-21 | 2016-10-27 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| WO2017213910A1 (en) * | 2016-06-06 | 2017-12-14 | Eli Lilly And Company | Mutant idh1 inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015012822A (es) * | 2013-03-14 | 2016-05-31 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante. |
| WO2014147586A1 (en) * | 2013-03-22 | 2014-09-25 | Novartis Ag | 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh |
| GB2552283A (en) * | 2015-04-24 | 2018-01-17 | Halliburton Energy Services Inc | Methods of fabricating ceramic or intermetallic parts |
| WO2017019429A1 (en) * | 2015-07-27 | 2017-02-02 | Eli Lilly And Company | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors |
| JP6793836B2 (ja) * | 2016-12-16 | 2020-12-02 | イーライ リリー アンド カンパニー | 変異体ｉｄｈ１およびｉｄｈ２阻害剤としての７−フェニルエチルアミノ−４ｈ−ピリミド［４，５−ｄ］［１，３］オキサジン−２−オン化合物 |
-
2017
- 2017-12-08 JP JP2019532088A patent/JP6793836B2/ja active Active
- 2017-12-08 HU HUE17822882A patent/HUE052067T2/hu unknown
- 2017-12-08 TN TNP/2019/000158A patent/TN2019000158A1/en unknown
- 2017-12-08 EA EA201991161A patent/EA036112B1/ru not_active IP Right Cessation
- 2017-12-08 MX MX2019006830A patent/MX385562B/es unknown
- 2017-12-08 PL PL17822882T patent/PL3555105T3/pl unknown
- 2017-12-08 CN CN201780078017.0A patent/CN110072867B/zh active Active
- 2017-12-08 UA UAA201905584A patent/UA123640C2/uk unknown
- 2017-12-08 HR HRP20201882TT patent/HRP20201882T1/hr unknown
- 2017-12-08 ES ES17822882T patent/ES2835281T3/es active Active
- 2017-12-08 NZ NZ754115A patent/NZ754115A/en unknown
- 2017-12-08 MA MA47399A patent/MA47399B1/fr unknown
- 2017-12-08 PH PH1/2019/501328A patent/PH12019501328B1/en unknown
- 2017-12-08 CR CR20190252A patent/CR20190252A/es unknown
- 2017-12-08 ES ES20189241T patent/ES2941631T3/es active Active
- 2017-12-08 SI SI201730488T patent/SI3555105T1/sl unknown
- 2017-12-08 WO PCT/US2017/065246 patent/WO2018111707A1/en not_active Ceased
- 2017-12-08 LT LTEP17822882.1T patent/LT3555105T/lt unknown
- 2017-12-08 AU AU2017378060A patent/AU2017378060B2/en active Active
- 2017-12-08 JO JOP/2019/0142A patent/JOP20190142B1/ar active
- 2017-12-08 DK DK17822882.1T patent/DK3555105T3/da active
- 2017-12-08 MY MYPI2019003350A patent/MY197313A/en unknown
- 2017-12-08 MA MA053881A patent/MA53881A/fr unknown
- 2017-12-08 KR KR1020197016855A patent/KR102276022B1/ko active Active
- 2017-12-08 PE PE2019001077A patent/PE20190977A1/es unknown
- 2017-12-08 PT PT178228821T patent/PT3555105T/pt unknown
- 2017-12-08 RS RS20201429A patent/RS61108B1/sr unknown
- 2017-12-08 CA CA3045303A patent/CA3045303C/en active Active
- 2017-12-08 US US16/349,873 patent/US11001596B2/en active Active
- 2017-12-08 CN CN202210758386.7A patent/CN115109075B/zh active Active
- 2017-12-08 EP EP20189241.1A patent/EP3763717B1/en active Active
- 2017-12-08 MD MDE20191188T patent/MD3555105T2/ro unknown
- 2017-12-08 EP EP17822882.1A patent/EP3555105B1/en active Active
-
2019
- 2019-05-17 ZA ZA2019/03125A patent/ZA201903125B/en unknown
- 2019-05-23 CO CONC2019/0005287A patent/CO2019005287A2/es unknown
- 2019-05-30 SA SA519401897A patent/SA519401897B1/ar unknown
- 2019-06-06 CL CL2019001551A patent/CL2019001551A1/es unknown
- 2019-06-11 IL IL267236A patent/IL267236B/en active IP Right Grant
- 2019-06-11 DO DO2019000163A patent/DOP2019000163A/es unknown
- 2019-06-14 EC ECSENADI201942682A patent/ECSP19042682A/es unknown
-
2020
- 2020-10-29 AU AU2020260493A patent/AU2020260493B2/en active Active
- 2020-11-25 CY CY20201101122T patent/CY1123577T1/el unknown
-
2021
- 2021-03-16 US US17/202,515 patent/US11649247B2/en active Active
- 2021-03-16 US US17/202,867 patent/US11629156B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013046136A1 (en) * | 2011-09-27 | 2013-04-04 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| WO2016171755A1 (en) * | 2015-04-21 | 2016-10-27 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| WO2017213910A1 (en) * | 2016-06-06 | 2017-12-14 | Eli Lilly And Company | Mutant idh1 inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020260493B2 (en) | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | |
| EP3328866B1 (en) | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors | |
| JP6744489B2 (ja) | 癌の治療において有用な６，７，８，９−テトラヒドロ−３Ｈ−ピラゾロ［４，３−ｆ］イソキノリン誘導体 | |
| JP6682043B2 (ja) | 変異体ｉｄｈ１阻害剤 | |
| KR20160140739A (ko) | 마크로사이클릭 피리미딘 유도체 | |
| HK40008100B (en) | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors | |
| HK40008100A (en) | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors | |
| BR112019009648B1 (pt) | Compostos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]oxazin-2-ona como inibidores de idh1 e idh2 mutantes, composição farmacêutica que os compreende e seu uso | |
| WO2025238550A1 (en) | Creatine kinase inhibitors | |
| HK40026812B (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |